Continuous glucose monitoring
Listening to your body, every day.
Constant blood sugar management for more informed daily decisions.
Continuous Glucose Monitoring (CGM) technology provides patients with real time information about their blood glucose levels, 24 hours a day, by means of a small sensor positioned on their skin.
This continually updated information enables CGM users to monitor their blood sugar levels constantly, intervene early and improve their diabetes management, thus reducing the risk of hypoglycaemia or hyperglycaemia.
Small on the outside, powerful on the inside
A CGM system consists of:
- A sensor inserted under the skin, which measures the patient’s glucose level once every few minutes.
- A transmitter, attached to or integrated into the sensor, which transmits the collected data to a receiver device, smart-phone or insulin pump.
- A visualisation device that displays real-time blood sugar values, trends and alarms if levels are too high or too low.
How continuous monitoring improves diabetes management.
- Reduction of hypoglycaemias: through continuous monitoring it is possible to detect falls in blood sugar levels before obvious symptoms appear, helping to prevent episodes of hypoglycaemia, even when inadvertent.
- Predictivity: some systems are also equipped with a 'predictive alarm' that warns the user of a possible impending hypoglycaemia or hyperglycaemia, based on the rate of change of glucose levels measured by the sensor.
- Greater awareness: the acquired data facilitates understanding of the impact of diet, physical activity and stress on blood sugar levels.
- Improved therapeutic adherence: access to blood sugar data, history and changes support more informed decisions, improving therapy management.
- Safety and peace of mind: sharing real-time blood glucose data and alerts with family members and caregivers ensures constant support and safety.
Continuous monitoring for
a safer and more informed life style.
By monitoring blood sugar levels continuously it is not only possible to reduce the risk of hypoglycaemic
and hyperglycaemic episodes, but it also enable the patient to make more informed
daily therapeutic choices in order to live a safer and more carefree life.
Customer testimonials*
Monitoraggio in continuo del glucosio 7 ENG
"I have been using the sensor for a few years and I can say that it has changed my life. Saying goodbye to constant finger pricking after so many years, knowing that your blood sugar level is always under control due to the reliability of the sensor, is priceless. My glycated haemoglobin has also improved, reaching near-normal values."
Monitoraggio in continuo del glucosio 6 ENG
"The sensor plays a key role in our diabetes management. The knowledge that we can intervene at an early stage and anticipate any situation positively influences our daily lives."
Monitoraggio in continuo del glucosio 5 ENG
"It has greatly simplified the management of my diabetes by significantly reducing the variations in my blood sugar levels, rendering them more stable."
Monitoraggio in continuo del glucosio 4 ENG
"Since using CGM, diabetes management has radically changed my daily life, making me feel more confident and relaxed during the actions I have to carry out at any time of the day."
Moniotoraggio in continuo del glucosio 3 ENG
"The ability to monitor my blood sugar levels and receive personalised alarms allows me to act quickly and effectively, definitely helping me to keep my blood sugar steady over time."
Moniotoraggio in continuo del glucosio 2 ENG
"Simply fantastic and very useful. Life before the sensor was complicated, monitoring glucose was almost impossible, I often neglected to up prick my finger to measure my values because everyday life got in the way."
Monitorggio in continuo del glucosio 1 ENG
"Using the system makes diabetes management easier and more controllable. You are constantly informed about blood sugar values and alerted in advance in the event of hypoglycaemia and hyperglycaemia, so that such episodes can be dealt with immediately or even prevented.
*Customer testimonials were acquired anonymously through the TherasCare website and represent personal, real-world experiences based on individual responses to treatment. While these experiences are authentic, they do not guarantee that all users will experience the same results.
To assess whether the system is suitable for you, always consult your diabetes specialist.
Sources
- ADA Diabetes Technology: Standards of Care in Diabetes—2025
- Preechasuk et al. 2024. “Switching from Intermittently Scanned Continuous Glucose Monitoring to Real-Time Continuous Glucose Monitoring with a Predictive Urgent Low Soon Alert Reduces Exposure to Hypoglycemia”. Diabetes Technol Ther.
- Acciaroli et al. 2023. “G6 continuous glucose monitoring system feature use and its associations with glycaemia in Europe”. Diabet Med
- Acciaroli, et al. 2021. “Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts”. Journal of Diabetes Science and Technology.
- Visser, et al. 2021. “Comparing Real-Time and Intermittently Scanned Continuous Glucose Monitoring in Adults with Type 1 Diabetes (ALERTT1): A 6-Month, Prospective, Multicentre, Randomised Controlled Trial.” The Lancet.
- DiMeglio et al. 2021. “A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes.” Diabetes Care.
- Lind et al. 2021. “Sustained Intensive Treatment and Long-Term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI.” Diabetes Care.
- Pratley et al. 2020. “Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial”. JAMA.
- Laffel et al. 2020. “Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial.” JAMA.
- Hood et al. 2020. “Use of Factory-Calibrated Real-Time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study.” Diabetes Care.
- ADA Diabetes Technology: Standards of Care in Diabetes—2025
- Linea Guida della Associazione dei Medici Diabetologi (AMD), della Società Italiana di Diabetologia (SID) e della Società Italiana di Endocrinologia e Diabetologia Pediatrica (SIEDP). - La terapia del diabete mellito di tipo 1. 2024